Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: An open-label randomized controlled trial

BMC Infectious Diseases

Volumn 17, Issue 1, 2017, Pages

  Rattanaumpawan, Pinyo ^a   Werarak, Peerawong ^a   Jitmuang, Anupop ^a   Kiratisin, Pattarachai ^a   Thamlikitkul, Visanu ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Carbapenem; De escalation; Enterobacteriaceae; Ertapenem; ESBL

Indexed keywords

CARBAPENEM; ERTAPENEM; MEROPENEM; ANTIINFECTIVE AGENT; BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BACTEREMIA; CANDIDA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ERADICATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE INFECTION; FEMALE; GASTROINTESTINAL INFECTION; GENITAL TRACT INFECTION; HEADACHE; HOSPITALIZATION; HUMAN; INFECTION RATE; LENGTH OF STAY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY RATE; OPEN STUDY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; URINARY TRACT INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; GENETICS; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 85014356090     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-017-2284-1     Document Type: Article

References (17)

1. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.
2. Shlaes DM, Gerding DN, John Jr JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25(3):584-99.
3. Antonelli M, Mercurio G, Di Nunno S, Recchioni G, Deangelis G. De-escalation antimicrobial chemotherapy in critically III patients: pros and cons. J Chemother. 2001;13(1):218-23.
4. Masterton RG. Antibiotic de-escalation. Crit Care Clin. 2011;27(1):149-62.
5. Leone M, Bechis C, Baumstarck K, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med. 2014;40(10):1399-408.
6. Mokart D, Slehofer G, Lambert J, et al. De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study. Intensive Care Med. 2014;40(1):41-9.
7. Lew KY, Ng TM, Tan M, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother. 2015;70(4):1219-25.
8. Zhanel GG, Johanson C, Embil JM, et al. Ertapenem: review of a new carbapenem. Expert Rev Anti-Infect Ther. 2005;3(1):23-39.
9. Falagas ME, Tansarli GS, Kapaskelis A, Vardakas KZ. Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review. Expert Rev Anti-Infect Ther. 2013;11(1):69-78.
10. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(12):2793-803.
11. Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections. Int J Antimicrob Agents. 2007;30(4):356-9.
12. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother. 2008;42(2):207-12.
13. Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012;56(4):2173-7.
14. Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016;71(6):1672-80.
15. Musson DG, Majumdar A, Birk K, et al. Pharmacokinetics of intramuscularly administered ertapenem. Antimicrob Agents Chemother. 2003;47(5):1732-5.
16. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309-32.
17. Institute CaLS. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement: M100-S21: Wayne, Clinical Lab Standards Institute. 2011.